Taxotere Hair Loss Articles
July 18, 2017. By Deb Hipp.
New Orleans, LA: Plaintiffs in a Louisiana multidistrict Taxotere litigation have asked the court to remand several cases back to state courts.Read [ Taxotere Multidistrict Litigation May Remand Some Cases to State Courts ]
July 6, 2017. By Gordon Gibb.
Washington, DC: Many a Taxotere hair loss lawsuit asserts that the manufacturer of Taxotere (docetaxel), Sanofi, knew about the increased risk for permanent hair loss associated with its cancer drug, and yet downplayed the risk without revealing that competing products on the market were just as effective at treating cancer as Taxotere, but without the corresponding increased risk for permanent hair loss, or so it is alleged.Read [ Taxotere Hair Loss: Are Doctors Forthright with their Patients as to Risk? ]
June 19, 2017. By Gordon Gibb.
New Orleans, LA: Understanding the choice that some women make in their selection of Taxotere for treatment of breast cancer, means understanding the busy lives and compelling responsibilities that modern women maintain. It is also easy to understand why plaintiffs embroiled in Taxotere hair loss lawsuits, may have been misled over the potential for permanent Taxotere alopecia.Read [ Permanent Taxotere Hair Loss for Cancer Patients a Particularly Cruel Fate ]
June 3, 2017. By Deb Hipp.
New Orleans, LA: A Louisiana multidistrict litigation (MDL) that began in 2016 with less than three dozen transferred Taxotere lawsuits has now swelled to more than a thousand pending cases.Read [ Number of Taxotere Multidistrict Litigation Cases Surpass 1,100 ]
May 24, 2017. By Brenda Craig.
Philadelphia, PA Eight Manufacturers of a generic form of Taxotere known as Docetaxel are also being included in the ongoing MDL in U.S. District Court, Eastern District of Louisiana (New Orleans). As a result, more women will likely join the approximately 1,000 women already involved in the litigation.Read [ Generic Docetaxel Inclusion in Taxotere MDL Significant Departure ]
May 15, 2017. By Gordon Gibb.
Washington, DC: A recent filing by Taxotere manufacturer Sanofi Aventis with the US Securities and Exchange Commission (SEC) revealed the current state of Taxotere hair loss lawsuits as of the end of the pharmaceutical’s fiscal year ending December 31, 2016.Read [ Taxotere Hair Loss Patients Speak Out Over the Fallout ]
April 20, 2017. By Gordon Gibb.
New Orleans, LA: An interesting sidebar to Taxotere hair loss litigation has opened up through a peek into docetaxel hair loss multidistrict litigation, and an accompanying analysis of the various approval protocols employed to bring both branded and generic docetaxel (Taxotere) to the market.Read [ Pharmaceuticals Fast-Tracked to Market through Little-Known FDA Protocol ]
April 7, 2017. By Deb Hipp.
New Orleans, LA A multidistrict litigation of hundreds of Taxotere lawsuits alleging that the chemotherapy drug Taxotere causes permanent hair loss continues to move forward in federal court with a "Science Day" scheduled in May.Read [ Science Day Scheduled For Taxotere Multidistrict Litigation ]
March 29, 2017. By Brenda Craig.
San Francisco, CA In 2010, Ami Dodson was diagnosed with stage two breast cancer and underwent a partial mastectomy to remove the cancer. Her oncologists suggested they follow up with chemotherapy treatments using a drug known as Taxotere. Her prognosis was excellent and there was every expectation she would live a normal life.Read [ California Women Suffers Permanent Hair Loss after Taxotere Chemo – Suit Claims ]
March 4, 2017. By Gordon Gibb.
New Orleans, LA: As important as it is to be aware of any, and all side effects associated with a drug such as Taxotere, patients in need of the chemotherapy drug are already coming from a position of significant physical and emotional challenge: the fallout from a cancer diagnosis. And while most cancer patients are aware that hair loss is a common byproduct of chemotherapy and cancer treatments, many would not be cognizant about the potential for Taxotere hair loss to be permanent.Read [ Potential for Permanent Taxotere Hair Loss Not Widely Promoted ]